This article appears in the following Journal of Antimicrobial Chemotherapy issue: The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project 1999/2000-2006/7 [View the issue table of contents]
Articles |
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001–06
1 Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK 2 Department of Medical Microbiology, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK
* Correspondence address. Antibiotic Resistance Monitoring and Reference Laboratory, HPA Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK. Tel: +44-20-8327-6493; Fax: +44-20-8327-6264; E-mail: russell.hope{at}hpa.org.uk
Objectives: Investigation of the antibiotic susceptibilities and trends for staphylococci collected from bacteraemia cases in the UK and Ireland, from 2001 to 2006, as part of the British Society for Antimicrobial Chemotherapy's Bacteraemia Surveillance Programme.
Methods: Twenty-five hospitals from the UK and Ireland each collected up to 10 consecutive isolates of both Staphylococcus aureus and coagulase-negative staphylococci (CoNS) per year from 2001 to 2006. MIC determination and identification to species level were carried out centrally. mecA and also mupA alleles were sought by PCR in S. aureus and CoNS from 2005 and 2006, respectively.
Results: One thousand four hundred and forty-eight S. aureus and 1214 CoNS were collected. The overall prevalence of methicillin resistance was 42% (with 
6% annual fluctuation) for S. aureus and 67% (range 54% to 80%) for CoNS. Resistance to aminoglycosides, macrolides, quinolones and tetracyclines was strongly associated with methicillin resistance in both species groups. Many (20.8%) CoNS and three (0.2%) S. aureus isolates were non-susceptible to teicoplanin, but there was no vancomycin non-susceptibility found in S. aureus and only one vancomycin-intermediate CoNS isolate. There was little evidence of susceptibility trends over time for any antibiotic, with the surveillance period preceding the recent fall in methicillin-resistant S. aureus (MRSA) prevalence indicated by the mandatory surveillance of MRSA bacteraemia in England. The newer antibiotics, ceftobiprole, daptomycin, linezolid, telavancin and tigecycline, all had excellent activity against staphylococci.
Conclusions: Multiresistant staphylococci remain abundant in the UK and Ireland but many new antimicrobials are becoming available and these may prove effective alternatives to glycopeptides.
Keywords: Prevalence , MRSA , surveillance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Pantosti and M. Venditti What is MRSA? Eur. Respir. J., November 1, 2009; 34(5): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Livermore Has the era of untreatable infections arrived? J. Antimicrob. Chemother., September 1, 2009; 64(suppl_1): i29 - i36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds Antimicrobial resistance in the UK and Ireland J. Antimicrob. Chemother., September 1, 2009; 64(suppl_1): i19 - i23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, and on behalf of the MRSA Working Party of the British Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom J. Antimicrob. Chemother., May 1, 2009; 63(5): 849 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. White and on behalf of the BSAC Working Parties on Resistanc The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii3 - ii14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds, R. Hope, L. Williams, and on behalf of the BSAC Working Parties on Resistanc Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii15 - ii28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds, P. C. Lambert, P. R. Burton, and on behalf of the BSAC Extended Working Parties on Analysis, power and design of antimicrobial resistance surveillance studies, taking account of inter-centre variation and turnover J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii29 - ii39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Future directions with daptomycin J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii41 - iii49. [Abstract] [Full Text] [PDF]
|
|